- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02544074
Validity of the Electronic Self-Administered Gerocognitive Examination (eSAGE) (eSAGE)
The Self-Administered Gerocognitive Examination (SAGE) is a valid and reliable cognitive assessment tool used to identify both Mild Cognitive Impairment (MCI) and early dementia. SAGE's self-administered feature, pen and paper format, and four equivalent interchangeable forms allows it to be given in almost any setting, does not require any staff time to administer and makes it practical to rapidly screen large numbers of individuals in the community or in their home.This trial is being conducted to study the validity of SAGE in a digital format (eSAGE) for cognitive screening.
The investigators will analyze the data to learn the correlations between eSAGE and gold standard neuropsychological testing designed to differentiate normal cognition from MCI and early dementia. The investigators will also find out whether the paper (SAGE) and electronic (eSAGE) versions of SAGE could be used interchangeably or not.
Addendum:
The eSAGE was previously validated in an earlier stage of this trial. It was initially designed for tablet use and the exact same test has recently been formatted for smartphone use.
This addendum is being conducted to study the validity of the smartphone eSAGE compared to the tablet eSAGE for cognitive screening.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Participants will be recruited based on their eSAGE scores and evaluated with neuropsychological testing and medical history to determine their status as normal, mild cognitive impairment, or dementia.
The investigators will analyze the data to learn the correlations between eSAGE and gold standard neuropsychological testing designed to differentiate normal cognition from MCI and early dementia. The investigators will also find out whether the paper (SAGE) and electronic (eSAGE) versions of SAGE could be used interchangeably or not.
Addendum:
Subjects will be scheduled for a one time visit where they will be administered both the tablet eSAGE and the smartphone eSAGE. eSAGE tablet scores will be compared to eSAGE smartphone scores to determine if the two formats are equivalent to each other.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43221
- The Ohio State University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Subjects will be recruited from a wide variety of community events including senior centers, health fairs, educational talks to lay public, independent and assisted living facilities, and free memory screens as well as from ambulatory Geriatric or Memory Disorders Clinics. The SAGE cognitive screening tool will be given to all subjects willing to take the test.Participants who complete the SAGE test and meet inclusion and exclusion criteria will be divided into groups based on their initial SAGE scores. Each group will be composed of subjects with the same score. Individuals will be randomly selected from each group and asked to further participate in a one-time clinical evaluation.
Addendum:
Subjects will be recruited from community events and our clinic and research center.
Description
Inclusion Criteria:
- Adults over 49 years old of either gender
- Vision and hearing sufficient for compliance with tests
Exclusion Criteria:
- Diagnosis by a physician of moderate or severe dementia
- Intellectual disability
Study Plan
How is the study designed?
Design Details
- Observational Models: Other
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
eSAGE score of 10
Participants who score a 10 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 11
Participants who score an 11 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 12
Participants who score a 12 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 13
Participants who score a 13 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 14
Participants who score a 14 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 15
Participants who score a 15 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 16
Participants who score a 16 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 17
Participants who score a 17 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 18
Participants who score a 18 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 19
Participants who score a 19 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 20
Participants who score a 20 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 21
Participants who score a 21 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 22
Participants who score a 22 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 9
Participants who score a 9 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 8
Participants who score an 8 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 6
Participants who score a 6 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 7
Participants who score a 7 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 5
Participants who score a 5 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 4
Participants who score a 4 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 3
Participants who score a 3 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
eSAGE score of 2
Participants who score a 2 on the eSAGE.
Interventions include neuropsychological testing.
|
standard neuropsychological testing including brief standardized assessments
|
Smartphone eSAGE score of 13
Participants who score a 13 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 14
Participants who score a 14 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 15
Participants who score a 15 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 16
Participants who score a 16 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 17
Participants who score a 17 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 18
Participants who score a 18 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 19
Participants who score a 19 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 20
Participants who score a 20 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 21
Participants who score a 21 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
Smartphone eSAGE score of 22
Participants who score a 22 on the smartphone eSAGE.
Interventions include neuropsychological testing.
|
Neuropsychological testing including the eSAGE tablet and eSAGE smartphone
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
eSAGE Score Compared to the Sum of the Neuropsychological Measures.
Time Frame: 3 Hours
|
Analysis will consist of comparing the subject's scores on the SAGE in digital format to their neuropsychological test scores. This will be a composite score of the neuropsychological testing scores. The neuropsychological measures include:
Associations will be investigated using Spearman correlations. |
3 Hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
eSAGE Score Compared to the Paper SAGE Score
Time Frame: 3 hours
|
The investigators will compare the subject's scores on the SAGE in digital format to their paper SAGE scores to determine if these two formats are equivalent to each other.
Associations will be investigated using Spearman correlations.
|
3 hours
|
eSAGE Score Compared to the Mini-Mental State Examination (MMSE) Score
Time Frame: 3 hours
|
The investigators will compare the eSAGE scores with the Mini-Mental State Examination (MMSE) scores.
Associations will be investigated using Spearman correlations.
|
3 hours
|
eSAGE Score Compared to the Montreal Cognitive Assessment (MoCA) Score
Time Frame: 3 hours
|
The investigators will compare the eSAGE scores with the Montreal Cognitive Assessment (MoCA) scores.
Associations will be investigated using Spearman correlations.
|
3 hours
|
eSAGE Score Compared to the Boston Naming Test Score
Time Frame: 3 hours
|
The investigators will compare the eSAGE scores to the Boston Naming Test score.
The Boston Naming Test consists of 60 pictures of nouns that subjects must try to name.
Associations will be investigated using Spearman correlations.
|
3 hours
|
eSAGE Score Compared to the Wisconsin Card Sort Task (WCST) Score
Time Frame: 3 hours
|
The investigators will compare the eSAGE scores to the Wisconsin Card Sort Task (WCST) perseverative errors scores.
Associations will be investigated using Spearman correlations.
|
3 hours
|
eSAGE Score Compared to the Hopkins Verbal Learning Test (HVLT) Score
Time Frame: 3 hours
|
The investigators will compare the eSAGE scores to the Hopkins Verbal Learning Test (HVLT) total learning scores.
Associations will be investigated using Spearman correlations.
The investigators will also compare the eSAGE scores to the Hopkins Verbal Learning Test (HVLT) delayed recall scores.
Associations will be investigated using Spearman correlations.
|
3 hours
|
eSAGE Score Compare to the FAS Verbal Fluency Task Score
Time Frame: 3 hours
|
The investigators will compare the eSAGE scores to the FAS Verbal Fluency Task scores.
Associations will be investigated using Spearman correlations.
|
3 hours
|
eSAGE Score Compared to the Wechsler Adult Intelligence Scale III (WAIS III) Letter-number Score
Time Frame: 3 hours
|
The investigators will compare the eSAGE scores to the WAIS III Letter-number scores.
The WAIS III Letter-number test asks subjects to recall a series of numbers in increasing order and letters in alphabetical order.
Associations will be investigated using Spearman correlations.
|
3 hours
|
eSAGE Score Compared to the Wechsler Adult Intelligence Scale III (WAIS III) Block Design Score
Time Frame: 3 hours
|
The investigators will compare the eSAGE scores to the WAIS III Block Design scores.
The WAIS III Block Design requires the replication of red and white designs using three-dimensional colored blocks.
Associations will be investigated using Spearman correlations.
|
3 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Douglas Scharre, M.D., Ohio State University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014H0039
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on neuropsychological testing
-
Fondazione Policlinico Universitario Agostino Gemelli...Recruiting
-
Stanford UniversityWashington University School of Medicine; University of Wisconsin, MadisonCompletedCarotid Artery StenosisUnited States
-
University of South FloridaUnknown
-
University of South FloridaMayo Clinic; Florida Department of Health; Mt. Sinai Medical Center, MiamiUnknown
-
Hadassah Medical OrganizationWithdrawn
-
First Affiliated Hospital of Harbin Medical UniversityRecruitingCerebrovascular Disease Small VesselChina
-
University Hospital, RouenUnknownCerebrovascular Disorders | Brain Lesions | Degenerative Diseases | Developmental PathologyFrance
-
Charite University, Berlin, GermanyNot yet recruiting
-
Stanford UniversityNot yet recruiting
-
Rehabilitation Hospital of IndianaNot yet recruitingNeuropsychology | Testing